Science：科学家开发出候选疫苗成功抵御MERS的感染

2015-12-21 佚名 s生物谷

近日，一项发表于国际杂志Science上的研究论文中，来自德国和荷兰的研究团队通过研究开发出了成功对单峰骆驼进行免疫来抵御MERS病毒的感染，由于目前骆驼是病毒主要的储存宿主，因此新型疫苗的开发或可有效帮助降低MERS病毒在人群中的感染和爆发。近来和MERS病毒相关的冠状病毒可以引发人类出现感染性的呼吸系统疾病，尤其对人类是致死性的；该病毒被认为可以通过接触单峰驼来进行人间传播，如今研究人

近日，一项发表于国际杂志Science上的研究论文中，来自德国和荷兰的研究团队通过研究开发出了成功对单峰骆驼进行免疫来抵御MERS病毒的感染，由于目前骆驼是病毒主要的储存宿主，因此新型疫苗的开发或可有效帮助降低MERS病毒在人群中的感染和爆发。

近来和MERS病毒相关的冠状病毒可以引发人类出现感染性的呼吸系统疾病，尤其对人类是致死性的；该病毒被认为可以通过接触单峰驼来进行人间传播，如今研究人员成功开发出了一种可以抵御病毒感染的候选疫苗，而且研究者也首次利用这种新型疫苗有效地降低了骆驼机体中的病毒载量。

研究者Sutter表示，这种名为MVA-MERS-S的新型疫苗早在2年前就被开发了，研究人员通过将表达MERS病毒纤突蛋白的基因引入到痘病毒的基因组中，随后对痘病毒进行修饰使其表达在感染细胞表面来表达MERS蛋白，而且这种工程化的痘病毒也就成为了开发新型疫苗的基础。初期研究结果阐明了MVA-MERS-S疫苗在小鼠机体中的效应和免疫效力，而本文中研究人员首次描述了该疫苗在骆驼机体中的反应。

研究人员发现，利用MVA-MERS-S进行免疫不仅可以帮助抵御MERS病毒的感染，而且还帮助抵御骆驼发生骆驼痘的出现。在感染MERS病毒的骆驼中，其机体的症状仅限于上呼吸道，而文章中研究者共感染了8只骆驼，其中一半都已经通过鼻内和肌肉法，在机体暴露病毒三周前都进行了免疫，在接种的骆驼机体中，疫苗可以诱导大量抗体的产生，从而帮助抑制病毒的复制以及感染性症状的发生。研究结果表明，MVA-MERS-S疫苗可以明显帮助减少骆驼鼻上皮中病毒的存在。

当然MVA-MERS-S疫苗也可以用于对人类进行免疫，目前该疫苗在进行人类临床试验之前满足了很多重要的条件，而研究人员希望调查该疫苗进行I期临床试验的效果。截至目前为止并没有新型的候选疫苗来有效预防流行病学大事件的流行，就在数个月前，即2015年夏季，就有超过180名个体在韩国感染了MERS病毒。研究者希望本文的研究结果对于开发有效治疗抵御MERS病毒感染的新型疫苗或新型疗法带来帮助。

原文出处：

Bart L. Haagmans1, Judith M. A. van den Brand1,et al.An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.Science.2015

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (16)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-28 仁者大医

#ERS#

58 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-06-25 12498f17m66暂无昵称

#候选疫苗#

72 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

170 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

215 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

156 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

183 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

182 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

93 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-03-14 忠诚向上

好好学习，继续研究

116 0
[GetPortalCommentsPageByObjectIdResponse(id=1878142, encodeId=a49718e8142f7, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Mar 28 22:16:00 CST 2016, time=2016-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sat Jun 25 12:16:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69269, encodeId=c0a96926946, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69270, encodeId=3aff692e041, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=215, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69271, encodeId=a421692e1d8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69272, encodeId=34c0692e2f8, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69273, encodeId=9463692e3dc, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:07:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69267, encodeId=9b2f6926e1d, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69268, encodeId=109f69268d1, content=好好学习，继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 12:06:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54688, encodeId=f04c54688fb, content=好东西，值得分享，学习了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Fri Jan 08 19:38:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
2016-01-08 andruhn

好东西，值得分享，学习了！

114 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

感染

Science：科学家开发出候选疫苗成功抵御MERS的感染

科室

工具

服务